Grifols, S.A. (GRFS) Stock Price, Quote & News - Stock Analysis (2024)

FAQs

Grifols, S.A. (GRFS) Stock Price, Quote & News - Stock Analysis? ›

Grifols SA has a consensus rating of Moderate Buy which is based on 1 buy ratings, 1 hold ratings and 0 sell ratings. What is Grifols SA's price target? The average price target for Grifols SA is $16.87. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.

Grifols SA has a consensus rating of Moderate Buy which is based on 1 buy ratings, 1 hold ratings and 0 sell ratings. What is Grifols SA's price target? The average price target for Grifols SA is $16.87. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.

GRF Stock Forecast FAQ

Based on analyst ratings, Grifols, SA's 12-month average price target is €13.45.

Market cap: $6.02 Billion

As of August 2024 Grifols has a market cap of $6.02 Billion. This makes Grifols the world's 2374th most valuable company by market cap according to our data.

Grifols SA ADR is listed and trades on the NASDAQ stock exchange.

Historical dividend payout and yield for Grifols, S.A (GRFS) since 2015. The current TTM dividend payout for Grifols, S.A (GRFS) as of August 02, 2024 is $0.00. The current dividend yield for Grifols, S.A as of August 02, 2024 is 0.00%.

Intrinsic Value. The intrinsic value of one GRF stock under the Base Case scenario is 22.787 EUR. Compared to the current market price of 9.298 EUR, Grifols SA is Undervalued by 59%.

To lay off approximately 2,300 employees, most of whom are in the U.S., with approximately one-third located in Spain. Grifols announced a comprehensive operational restructuring plan designed to reinforce its competitiveness and build a more streamlined, efficient and cost-effective global organization.

Grifols, S.A. Stock Prediction 2025

The Grifols, S.A. stock prediction for 2025 is currently $ 7.37, assuming that Grifols, S.A. shares will continue growing at the average yearly rate as they did in the last 10 years.

Main products

Grifols is the major world supplier of IVIG, albumin, Factor VIII and other plasma-derived products.

What is the total debt of Grifols? ›

Total debt on the balance sheet as of June 2024 : $11.40 B

According to Grifols's latest financial reports the company's total debt is $11.40 B. A company's total debt is the sum of all current and non-current debts.

With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry.

BioLife Plasma Services is among the top payers in the plasma donation industry. New donors at BioLife can earn up to $900 in their first month through various promotions and bonuses.

Grifols acquires the company SeraCare, now Biomat, and its 43 plasma donation centers in the United States.

A qualified donor can donate plasma twice in every 7 days period at the most. You will receive up to $70 per donation.

There are more than 400 plasma donation centers spanning the U.S., Canada, Europe and Egypt.

ADMA Biologics's analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

Biocryst Pharmaceuticals has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

The average price target for FibroGen is $0.60. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $0.60 ,the lowest forecast is $0.60. The average price target represents 46.70% Increase from the current price of $0.409.